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Abstract 
 
Background: Four nonvitamin K antagonist oral anticoagulants (NOACs) have been approved for use 
in various cardiovascular indications. The direct thrombin inhibitor dabigatran and the direct factor 
Xa inhibitors apixaban, edoxaban, and rivaroxaban are now increasingly used in clinical practice. For 
some of these agents, available data from real-world studies support the efficacy and safety data in 
phase III clinical trials. 
Objectives: This review aims to summarize the current status of trials and observational studies of 
oral anticoagulant use over the spectrum of cardiovascular disorders (excluding venous thrombosis), 
provide a reference source beyond stroke prevention for atrial fibrillation (AF) and examine the 
potential for novel applications in the cardiovascular field. 
Methods: We searched the recent literature for data on completed and upcoming trials of oral 
anticoagulants with a particular focus on rivaroxaban.  
Results: Recent data in specific patient subgroups, such as patients with AF undergoing catheter 
ablation or cardioversion, have led to an extended approval for rivaroxaban, whereas the other 
NOACs have ongoing or recently completed trials in this setting. However, there are unmet medical 
needs for several arterial thromboembolic-related conditions, including patients with: AF and acute 
coronary syndrome, AF and coronary artery disease undergoing elective percutaneous coronary 
intervention, coronary artery disease and peripheral artery disease, implanted cardiac devices, and 
embolic stroke of unknown source.  
Conclusion: NOACs may provide alternative treatment options in areas of unmet need, and 
numerous studies are underway to assess their benefit–risk profiles in these settings.  
 
Keywords: direct oral anticoagulant, factor Xa inhibitor, lifecycle management, rivaroxaban 
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Introduction 
 
The scope for the nonvitamin K antagonist oral anticoagulants (NOACs) includes a range of 
cardiovascular diseases (CVDs), including coronary artery disease (CAD), cerebrovascular disease, 
atrial fibrillation (AF), peripheral artery disease (PAD), and venous thromboembolism (VTE). AF, the 
most prevalent cardiac condition with an anticoagulant indication, affects 0.7–3% of the population 
and prevalence increases with age [1-5]. It predisposes patients to develop left atrial (LA)/left atrial 
appendage (LAA) thrombus [6], and stroke risk is increased 5-fold [7]. Acute coronary syndrome 
(ACS) onset involves atheromatous plaque disruption or erosion complicated by platelet aggregation 
and thrombosis. Thrombosis may also be implicated in the consequences of myocardial infarction 
(MI), including left ventricular dysfunction, heart failure (HF), arrhythmia development, and VTE. For 
secondary prevention in ACS, guidelines recommend dual antiplatelet therapy (DAPT; acetylsalicylic 
acid [ASA] plus clopidogrel, prasugrel, or ticagrelor) [8-12]. However, even with antiplatelet therapy, 
the annual risk of cardiovascular death, nonfatal MI, or stroke remains ~10% [13], prompting a re-
evaluation of the role of combined anticoagulant and antiplatelet therapy [13]. 
 
Several studies have assessed the efficacy and safety of anticoagulants in arterial disease. The SAVE 
(Survival and Ventricular Enlargement) trial suggested that anticoagulation therapy (warfarin or 
heparin) protects against stroke after MI, but this study predated modern revascularization and 
antiplatelet therapy [14]. A meta-analysis of observational studies concluded that warfarin was more 
effective for the prevention of thrombosis in patients with transmural anterior MI than antiplatelet 
therapy alone [15]. However, in other studies, low-dose warfarin plus ASA was not more effective 
than ASA alone, and high-intensity warfarin without ASA increased bleeding risk in CVD secondary 
prevention [12]. 
More recently, NOACs were developed to improve anticoagulation consistency, without routine 
coagulation monitoring or food–drug and drug–drug interactions of vitamin K antagonists (VKAs). 
Phase III studies with dabigatran [16], rivaroxaban [17], apixaban [18], and edoxaban [19] showed 
that NOACs were as good as or better than warfarin for the prevention of stroke and systemic 
embolism (SE) in patients with nonvalvular AF (NVAF). The NOACs also significantly reduced 
intracranial hemorrhage (ICH) and mortality, with similar major bleeding rates, but often increased 
gastrointestinal bleeding risk versus warfarin [20]. Subgroup analyses (e.g., by age, history of stroke, 
and renal impairment) suggest that some NOACs have better benefit–risk profiles than others in 
specific patient groups [21]. All 4 NOACs are now approved for the prevention of stroke and SE in 
moderate-to-high-risk patients with AF in many countries; additionally, in Europe, rivaroxaban (2.5 
mg twice daily—a quarter of the AF dose) is approved in combination with antiplatelet therapy for 
secondary prevention after ACS in patients with elevated biomarkers (troponin or creatine kinase-
MB) [22-30]. Guidelines (e.g., from the American College of Chest Physicians [ACCP] and the 
European Society of Cardiology [ESC]) recommend NOACs for stroke prevention in high-risk patients 
with AF, either as an alternative option or in preference to warfarin (Supplemental Table 1) [6,31-35]. 
However, guidelines differ in their definitions of ‘high-risk’ patients and preferred scoring system. 
Ultimately, treatment decisions should be made on an individual basis for each patient and based on 
local guidelines [36]. 
 
Real-world data support the efficacy and safety of rivaroxaban, dabigatran, and apixaban in patients 
with AF reported in phase III studies (real-world data with edoxaban are not yet published) [37-45]. 
Several ongoing large-scale prospective studies or registries are continuously assessing the use of 
NOACs and their effectiveness and safety outcomes in patients with NVAF (Supplemental Table 2). In 
general, studies have shown that, in routine clinical practice, patients are generally more persistent 
and adherent to NOACs than VKAs and may have better long-term clinical outcomes [46,47]. 
 
Despite the established effectiveness and safety of the NOACs in stroke prevention in AF, best 
practice in specific scenarios is uncertain, although there are several completed and ongoing studies 
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in those settings (See Supporting Information, Table 1, in the online version of this article). The field 
is evolving rapidly, but lacks a reference source of current trials beyond stroke prevention in patients 
with AF. This review provides such a resource and examines the potential for new applications in the 
cardiovascular field. Recent data and upcoming studies that assess NOACs are summarized—with a 
focus on rivaroxaban—in a broad range of CVD indications, including cardioversion or catheter 
ablation, AF and ACS, AF and CAD with percutaneous coronary intervention (PCI), CAD, and PAD.  
 
Methods 
 
Using a predefined search strategy, PubMed, ClinicalTrials.gov and meeting abstracts were searched 
through September 2017 for data on completed and upcoming trials of oral anticoagulants in 
patients with cardiovascular disorders. All resulting studies and clinical trials were retrieved, 
reviewed, and checked for related publications. The following search terms were used: atrial 
fibrillation, cardioversion, catheter ablation, acute coronary syndrome, coronary and peripheral 
artery disease, percutaneous coronary intervention, heart failure, hypertrophic cardiomyopathy, 
atrial tachyarrhythmia, left atrial/left atrial appendage thrombi, valve disease, valve replacement, 
mitral stenosis, and antiphospholipid antibody syndrome (APS).  
 
Potential benefits of NOACs in patients with cardiovascular disorders: recent and current studies 
AF and stroke risk: real-world evidence 
International Medical Statistics Health data from 2014 indicate that factor Xa inhibitors (rivaroxaban, 
apixaban, and edoxaban) have a higher usage rate than thrombin inhibitors (dabigatran), and that 
rivaroxaban is the most commonly used factor Xa inhibitor [48]. 
 
Effectiveness and safety 
NOACs should demonstrate similar, or lower, rates of stroke/SE and major bleeding compared with 
warfarin in order to demonstrate clinical effectiveness. Several studies have compared the real-world 
effectiveness and safety of VKAs and NOACs such as rivaroxaban for stroke prevention in AF. These 
observational studies reflect use in clinical practice in populations without the inclusion and 
exclusion restrictions of phase III trials. The findings in these more inclusive populations underpin the 
effectiveness and safety of NOACs versus VKAs seen in phase III clinical trials [42-44,49-52]. In the 
prospective, international, noninterventional phase IV XANTUS (Xarelto for Prevention of Stroke in 
Patients with Atrial Fibrillation) study, stroke, and major bleeding rates were low in patients given 
rivaroxaban (mean CHADS2 score 2.0) [41]; major bleeding rate was lower than in the phase III 
ROCKET AF (Rivaroxaban Once daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation); (2.1 vs 3.6%/year, 
mean CHADS2 score in ROCKET AF 3.5) (Figure 1) [17,41,42,53,54]. Data from the Dresden NOAC 
Registry suggest that in a real-world setting, rates of major bleeding and outcomes with rivaroxaban 
may be better than or similar to those obtained with a VKA [42]. In a study assessing patients with AF 
from the Dresden NOAC Registry who received rivaroxaban, the rate of major bleeding was 3.0 per 
100 patient-years for the on-treatment population [53]. The rate of stroke, transient ischemic attack 
and SE was 2.0 per 100 patient-years in the intention-to-treat population [53]. In a similar study 
assessing patients with AF in the Dresden NOAC Registry who remained on a VKA, the rate of major 
bleeding was 4.2 per 100 patient-years, and the rate of stroke, transient ischemic attack and SE was 
1.3 per 100 patient-years in the intention-to-treat population [51]. Real-world studies have indicated 
a similar or decreased risk of ICH with rivaroxaban, apixaban, or dabigatran versus warfarin, 
consistent with the phase III clinical trial results [16,17,41,55-57]. Gastrointestinal bleeding risk is 
similar for rivaroxaban and warfarin in real-world settings [47,58,59]; findings for dabigatran versus 
warfarin have been inconsistent in this setting [37-39,58-61]. 
 
Most real-world effectiveness and safety outcomes data with NOACs versus VKAs are from 
retrospective database analyses, and outcomes are largely consistent with phase III trial results. For 
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example, a US Department of Defense claims database analysis indicated low rates of major bleeding 
with rivaroxaban (2.9%/year) [54]. Significantly lower rates of stroke with dabigatran versus warfarin 
(0.9%/year vs 1.3%/year; hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.55–0.97) and similar 
rates of major bleeding (3.1% vs 3.7%) were also observed, consistent with results for the dabigatran 
150 mg twice-daily dose in the phase III trial [16,62]. However, other studies have reported 
inconsistent effectiveness and safety outcomes versus other database analyses or phase III trial 
results [63]. These findings may be due to differences in patient characteristics and outcome 
definitions, and incomplete ascertainment of safety and efficacy outcomes in datasets extracted 
from routine records. There are also other factors that may affect data quality and limit the 
generalization of findings based on claims datasets. These include potential bias in drug and control 
group selection, coding errors, missing data, and varying or missing follow-up; therefore, 
retrospective datasets are insufficient, and prospective observational studies are required to support 
phase III study results. 
 
Treatment patterns 
The GARFIELD-AF (Global Anticoagulant Registry in the FIELD-AF) registry is a comprehensive 
multinational prospective program charting the evolving use of anticoagulants in patients with newly 
diagnosed AF. It examines treatment patterns (including no treatment), patient characteristics, and 
therapy choice in sequential cohorts [64]. Both men and women aged 18 and over, with a first 
diagnosis of NVAF within the previous 6 weeks, and with one or more investigator-defined risk 
factors for stroke, were included [64]. Cohorts were divided by date of enrollment (cohort 1 between 
March 2010 and October 2011; cohort 2 between August 2011 and June 2013; cohort 3 between 
April 2013 and October 2014; cohort 4 between March 2014 and July 2015; and cohort 5 between 
August 2015 and July 2016) [64]. Data from 39,670 patients in cohorts 1–4 showed that, since the 
introduction of the NOACs, newly diagnosed at-risk patients with AF increasingly receive guideline-
recommended therapy, driven by increased use of NOACs and reduced VKA use (with or without 
antiplatelets), and reduced use of antiplatelets alone in patients with CHA2DS2-VASc scores ≥2 [64]. 
Unpublished data from cohort 5 show a similar pattern to cohort 4 (Figure 2). However, because 
anticoagulant management was based on clinician decisions (rather than a risk score), the study 
observed use of anticoagulants and antiplatelets in patients without a risk score or other indication 
for anticoagulation (CHA2DS2-VASc score of 0) (Figure 2) [65]. 
 
Many patients given NOACs do not receive the appropriate dose [66,67], signifying a need for further 
education on appropriate dosing of NOACs. The extent of use of the lower dose of NOACs differs by 
anticoagulant, and for some agents this differs substantially from the use in the phase III trials 
[56,68]. Despite increasing use of anticoagulant therapy in line with guidelines, ~25% of patients with 
AF at risk of stroke still do not receive anticoagulation. Conversely, ≤40% of those at very low stroke 
risk (CHA2DS2-VASc score of 0) receive anticoagulation and/or antiplatelet therapy despite guideline 
recommendations [64]. 
 
Adherence/persistence 
Adherence relates to a patient acting in accordance with the prescribed interval and dose of the drug 
regimen (percentage of doses taken as prescribed) [69]. Persistence measures treatment duration 
and excludes permissible gaps [69]. 
 
In the Dresden NOAC Registry, persistence with therapy was analyzed using prescription refill data. 
Persistence was defined as ‘a refill within the period covered by the previous prescription or within 
60 days after the end of this period’ [70]. This included patients in whom treatment may have been 
interrupted but who received their following prescription within 60 days [70]. Persistence with 
therapy with rivaroxaban (66.0%) at 180 days was significantly higher than with VKA therapy (58.1%) 
in patients with AF [70]. Similarly, in 2 retrospective US database analyses, patients with AF were 
significantly more persistent at 6 months with rivaroxaban (74% and 82% persistent) than warfarin 
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(67% and 68% persistent) [46,47]. In 2 retrospective analyses of different US databases, rivaroxaban 
was associated with significantly higher persistence rates at 1-year follow-up, and significantly better 
adherence than dabigatran [71,72]. In a small-scale Canadian study, once-daily oral anticoagulant 
therapy was associated with better adherence than twice-daily therapy [73].  
 
These observational studies indicate that patients receiving rivaroxaban were significantly less likely 
to discontinue treatment versus other oral anticoagulants (8% for rivaroxaban vs 18% for warfarin; 
18% for dabigatran and 27% for apixaban; data for edoxaban are not yet available) [73].  
 
Specific patient subpopulations 
Despite the overall evidence for use of NOACs [6,31-35], there are specific situations for which there 
is a lack of clinical evidence. These include cardioversion, AF ablation, subclinical AF, dissolution of 
thrombi present in the LAA, concomitant AF and ACS, and patients with a high CHADS2/CHA2DS2-VASc 
score and no known AF. The latest European Heart Rhythm Association (EHRA) 2015 practical 
guidelines, and other recent consensus documents, advise how to manage selected, specific clinical 
situations [74-76], although they may need revision as trial evidence emerges. 
 
Cardioversion 
In patients with AF without adequate anticoagulation, cardioversion is associated with a 5–7% risk of 
thromboembolic events [77]. Thrombi are usually already present in the LAA or develop there after 
cardioversion [77]. Adequate anticoagulation in the weeks before cardioversion, or exclusion of 
patients with LA thrombi before the procedure, reduces this risk [77]. Guidelines recommend 
anticoagulation therapy before and after cardioversion, irrespective of CHADS2/CHA2DS2-VASc score 
or cardioversion method (electrical or pharmacological) [6,31]. An alternative way to reduce the risk 
of thromboembolic events without prior anticoagulation is to perform transesophageal 
echocardiogram (TEE)-guided cardioversion [77]. This procedure can establish the presence of a 
thrombus in the LA/LAA prior to cardioversion (incidence of LA thrombus in patients with AF pre-
cardioversion is ~7–12%) [77-79]. Therefore, if patient compliance with anticoagulation therapy is 
doubtful, patients undergoing cardioversion or ablation (see section 2.2 below) need to be assessed 
for the presence of an LA/LAA thrombus [74]. Immediate anticoagulation post-cardioversion is still 
required for up to 4 weeks because of the risk of thrombi developing after the procedure [77]. 
Improved strategies are needed because cardioversion frequently has to be rescheduled because of 
poor international normalized ratio control, and prolonged delays reduce restoration of sinus 
rhythm. 
 
Anticoagulation with warfarin or NOACs should continue for ≥4 weeks after cardioversion, based on 
ESC and American Heart Association (AHA)/ American College of Cardiology (ACC)/ Heart Rhythm 
Society (HRS) guidelines [31,80]. Post hoc analyses of phase III studies with dabigatran, rivaroxaban, 
and apixaban have shown the efficacy and safety of NOACs in patients with AF undergoing 
cardioversion [81-83]. The European approved indications for these 3 NOACs have, therefore, been 
extended to include continued use in cardioversion [23,25,27]. The prospective X-VeRT (eXplore the 
efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in 
subjects with non-valvular aTrial fibrillation scheduled for cardioversion) trial with rivaroxaban 
supports the findings of the post hoc analysis of ROCKET AF, but the sample size only allowed for a 
descriptive analysis [84,85]. Rivaroxaban administered de novo, as ongoing therapy, or instead of 
VKAs or another anticoagulant had a low risk of thromboembolic and bleeding events, similar to VKA 
treatment [84]. Rivaroxaban had similar risks to VKAs in both early and delayed cardioversion 
strategies, with a significantly shorter time to cardioversion in the delayed strategy group [84], 
resulting in the European approved indication for rivaroxaban being extended to include de novo 
rivaroxaban use in patients potentially undergoing cardioversion. In this case, rivaroxaban should be 
started ≥4 hours before cardioversion to ensure adequate anticoagulation before the procedure [23]. 
ENSURE-AF was a recent prospective trial comparing edoxaban with enoxaparin/warfarin in patients 
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undergoing cardioversion for NVAF. Efficacy and safety endpoint rates were low in each group [86]. A 
trial assessing apixaban in cardioversion is ongoing (EMANATE [NCT02100228]).  
 
Catheter ablation 
Catheter ablations are associated with a 0.3–0.4% incidence of clinically evident thromboembolic 
events, as observed in studies by Gaita et al. and Kirchhof et al. Interestingly, these studies also 
identified a proportion of patients with asymptomatic acute small cerebral lesions following catheter 
ablation, 14% and 26% respectively[87,88]. In the COMPARE trial, continuous warfarin therapy in 
patients undergoing catheter ablation reduced thromboembolic event rates [89], and guidelines 
recommend thromboprophylaxis in the peri-ablation setting [6,90]. Evidence that catheter ablation 
reduces stroke or mortality risk is lacking, but it is effective in controlling heart rhythm disorders and 
their symptoms. Practical guidance recommends ≥8 weeks’ post-procedure anticoagulation, 
depending on stroke risk [90]. 
 
Several studies have demonstrated that fewer complications occur with uninterrupted versus 
interrupted VKA; therefore, guidelines recommend continuous anticoagulation for patients receiving 
VKA during catheter ablation [6]. Nonrandomized studies using various dose–timing protocols 
suggest that the rate of major complications was low in patients undergoing catheter ablation with 
uninterrupted rivaroxaban, similar to other NOACs [91,92]. One retrospective study of uninterrupted 
warfarin or dabigatran versus a bridged warfarin strategy reported a higher rate of major 
complications with uninterrupted warfarin [93]. For continuous anticoagulation with NOACs, the lack 
of reversal agents in the ablation setting has initially been a barrier to use [94]. However, 
idarucizumab is now approved for use as a reversal agent for dabigatran, with promising ongoing 
studies for the reversal agents for the other NOACs, including andexanet alfa (reversal agent for 
apixaban, edoxaban, and rivaroxaban) and ciraparantag (reversal agent for several anticoagulants)  
[94]. 
 
VENTURE-AF was the first prospective trial of an uninterrupted NOAC versus a VKA in patients with 
AF undergoing catheter ablation; 248 patients were randomized to either uninterrupted rivaroxaban 
or uninterrupted VKA before catheter ablation and for 4 weeks post-ablation. There was 1 major 
bleeding event, 1 ischemic stroke, and 1 vascular death in the VKA group; no such events occurred in 
the rivaroxaban group [95]. Although small scale, this study suggests that use of uninterrupted 
rivaroxaban is feasible in this setting [95]. 
 
Other trials assessing the use of NOACs in the ablation setting are ongoing (See Supporting 
Information, Table 1, in the online version of this article). Data will become available over the coming 
years, and will inform treatment decisions.  
Secondary prevention of future cardiovascular events after ACS 
Several antithrombotic strategies have been tested for secondary prevention of coronary events, 
including DAPT with various antiplatelet combinations, a platelet-specific thrombin receptor 
antagonist (vorapaxar), and anticoagulation [96-104]. 
 
In the phase III ATLAS ACS 2 TIMI 51 (Anti-Xa Therapy to Lower cardiovascular events in Addition to 
aspirin with/without thienopyridine therapy in Subjects with Acute Coronary Syndrome) trial, 
rivaroxaban (2.5 mg or 5 mg twice daily) plus antiplatelet therapy (ASA alone or ASA plus clopidogrel) 
versus antiplatelet therapy alone reduced the risk of the composite of cardiovascular mortality, MI, 
and stroke in patients with a recent ACS [101]. Rivaroxaban increased major bleeding and ICH risk, 
but not fatal bleeding risk [101]. The most favorable benefit–risk profile was seen with rivaroxaban 
2.5 mg twice daily. The phase III APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events 2) 
trial assessed apixaban (full AF dose of 5 mg twice daily) plus standard antiplatelet therapy versus 
antiplatelet therapy alone in this setting. The study was prematurely terminated owing to increased 
major bleeding in the apixaban group (2.7% vs 1.1%; p<0.001) with no significant reduction in 
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cardiovascular death, MI or ischemic stroke compared with antiplatelet therapy alone (7.5% vs 7.9%, 
respectively; p=0.51) [103]. In a phase II, double-blind study, patients who had recently had an MI 
receiving dual antiplatelet therapy were randomized to dabigatran (various doses) or placebo [104]. 
Results showed that bleeding event rates were significantly higher with dabigatran (HR=1.77–4.27 
with increasing dose) versus placebo. However, dabigatran did demonstrate a significantly reduced 
level of coagulation activity (45% reduction at week 4; p<0.001) [104]; no phase III dabigatran study 
is currently underway. 
 
More recently, the phase II GEMINI ACS 1 (NCT02293395) trial demonstrated that rivaroxaban 2.5 mg 
twice daily had a similar bleeding risk to ASA in patients with a recent ACS who were receiving a P2Y12 
inhibitor. Similar efficacy outcomes were observed in both treatment arms, although the trial was 
not powered to detect a difference in efficacy [105]. 
 
In summary, rivaroxaban 2.5 mg twice daily in addition to antiplatelet therapy may provide greater 
clinical benefits compared with antiplatelet therapy alone (standard of care). Rivaroxaban is 
indicated for secondary prevention of cardiovascular events after an ACS event in patients with 
elevated cardiac biomarkers (troponin or creatine kinase-MB; approved by the European Medicines 
Agency [EMA] but not the US Food and Drug Administration [FDA]) [23]. The role of the other NOACs 
is uncertain and apixaban, dabigatran and edoxaban are currently not indicated for use in the post-
ACS setting. 
 
Coronary and peripheral artery disease 
Coronary artery disease and PAD often occur concomitantly; 1 study showed that 68% of patients 
aged >50 years with PAD also had CAD [106]. PAD affects 12–14% of the population and prevalence 
increases with age, affecting ≤20% of patients aged >75 years [107,108]. Patients with PAD have 
increased thrombogenicity and an increased relative risk of 3.1 (95% CI: 1.9–4.9) for all-cause 
mortality, and 5.9 (95% CI: 3.0–11.4) for cardiovascular mortality [109]. Because of the coexistence of 
CAD and cerebrovascular disease, PAD is associated with increased risk of cardiac and 
cerebrovascular events, in addition to obstructive disease of the lower extremities. Antiplatelet 
therapy can reduce the rate of the composite of cardiovascular death, MI, or stroke to <10% at the 
cost of increased minor bleeding; however, individual outcomes still occur in 2–20% of patients 
[110]. Revascularization strategies are also indicated to decrease the risk of limb loss, relieve 
symptoms, and improve quality of life [108]. 
 
In patients with PAD, the WAVE trial showed that a VKA plus ASA was no more effective than ASA 
alone in preventing cardiovascular complications, and increased the risk of life-threatening bleeding 
events [111]. Older trials support anticoagulation treatment in patients with CAD [112], and 
rivaroxaban is being assessed in this setting in phase III clinical trials (See Supporting Information, 
Table 1, in the online version of this article).  
 
The phase III COMPASS (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS) trial 
(NCT01776424) was stopped early after rivaroxaban 2.5 mg twice daily plus ASA clearly 
demonstrated efficacy in patients with CAD and/or PAD [113]. Rivaroxaban 2.5 mg twice daily plus 
ASA significantly reduced the composite incidence of cardiovascular death, stroke or MI, compared 
with ASA alone (4.1% vs 5.4%, HR: 0.76, 95% CI: 0.66–0.86, p < 0.001). In addition, rivaroxaban 2.5 
mg twice daily plus ASA was associated with a nominally significant reduction in all-cause mortality 
compared with ASA alone (3.4% vs 4.1%; p = 0.01; threshold for significance = 0.0025). The overall 
incidence of major bleeding was low but significantly increased with rivaroxaban 2.5 mg twice daily 
plus ASA, compared with ASA alone (rivaroxaban 2.5 mg twice daily plus ASA vs ASA alone: 3.1% vs 
1.9%, p < 0.001); there was no increase in fatal bleeding or intracranial hemorrhage. Rivaroxaban 5 
mg twice daily was also evaluated in COMPASS but did not demonstrate significant benefits in 
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efficacy outcomes compared with ASA alone and showed similar safety outcomes to rivaroxaban 2.5 
mg twice daily plus ASA [113].  
 
A subanalysis of the COMPASS data showed that the overall study outcomes were consistent in the 
subgroup of patients with PAD; importantly, rivaroxaban 2.5 mg twice daily plus ASA was associated 
with a significant 70% reduction in the incidence of major amputation in patients with PAD compared 
with ASA alone [114]. Additional data on the efficacy of rivaroxaban in patients with PAD will be 
provided by the phase III VOYAGER PAD trial (NCT02504216) in patients with PAD who have 
undergone recent procedures to improve peripheral blood flow. 
Patients with AF and CAD and those undergoing PCI 
Acute coronary syndrome is commonly associated with prevalent or incident AF, with an incidence of 
AF in ACS of 2.3–21% [115]. Concomitant AF and ACS increases mortality by 40% versus ACS alone 
[116-118]. There are insufficient data to guide clinical practice or identify the optimal antithrombotic 
therapy [119]. 
 
Patients with concomitant AF and ACS are challenging, because the combination of antiplatelet (ASA 
and/or a P2Y12 inhibitor) and anticoagulation therapy, especially at doses indicated for AF, increases 
annual risk of fatal and nonfatal bleeding episodes [120-122]. The WOEST (What is the Optimal 
antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) 
trial was the first randomized trial comparing single versus DAPT in VKA-treated patients undergoing 
PCI (~280 patients in each arm); ~70% of enrolled patients had AF as the indication for oral 
anticoagulation [123]. Treatment with clopidogrel and a VKA significantly lowered the risk of 
bleeding complications versus triple therapy with ASA, clopidogrel, and a VKA. Although the trial was 
small, there was no increased risk of thrombotic events with VKA plus single antiplatelet therapy 
[123]. Similar results were reported in a Danish registry study [124]. Based on the WOEST findings, 
the AHA/ACC/HRS guidelines recommend dual therapy with a VKA and clopidogrel [31]. By contrast, 
the 2016 ESC guidelines recommend initial triple therapy (VKA or NOAC, plus both clopidogrel and 
ASA), followed by dual therapy (VKA or NOAC, plus either clopidogrel or ASA) [80]. Because of the 
increased bleeding risk, triple therapy duration should be as short as possible [74]. 
 
Combined antiplatelet and anticoagulant therapies for the initial phase after PCI in patients with AF 
are recommended [6,31,74,75,125], but observational data suggest that combination therapies 
increase the risk of bleeding [124]. Several ongoing trials are assessing NOACs in this setting (See 
Supporting Information, Table 1, in the online version of this article); PIONEER AF-PCI (OPen-label, 
Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and 
a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation 
Who Undergo Percutaneous Coronary Intervention) demonstrated improved safety versus VKA in 
rivaroxaban-treated patients with ACS undergoing PCI [126]. As a consequence of PIONEER AF-PCI, 
rivaroxaban 15 mg once daily in combination with a P2Y12 inhibitor was approved for the treatment 
of patients with NVAF who require oral anticoagulation and undergo PCI with stent placement [23]. 
RE-DUAL PCI (Randomized Evaluation of DUAL antithrombotic therapy with dabigatran versus triple 
therapy with warfarin in patients with nonvalvular atrial fibrillation undergoing Percutaneous 
Coronary Intervention) demonstrated that two different regimens of full-dose anticoagulation 
therapy with dabigatran (either 110 mg or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or 
ticagrelor) resulted in a significantly lower risk of major or clinically relevant nonmajor bleeding 
events when compared with triple therapy with warfarin; in addition, dual therapy with dabigatran 
was noninferior to triple therapy with warfarin with respect to the composite efficacy endpoint of 
thromboembolic events, death, or unplanned revascularization.[127] 
 
Heart failure 
Heart failure constitutes a prothrombotic state, but evidence that an oral anticoagulant reduces 
mortality/morbidity in HF versus placebo or ASA is lacking [128]. However, phase III subanalyses 
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suggest that anticoagulation may benefit patients with HF and CAD. In a subgroup analysis of ATLAS 
ACS 2 TIMI 51, rivaroxaban 2.5 mg twice daily was associated with a lower rate of the composite of 
death from cardiovascular causes, MI, and stroke (primary efficacy outcome) versus placebo (11.6 vs 
18.6%) in patients with HF and ACS.  
 
Only one ongoing trial is assessing NOACs in patients with HF–COMMANDER-HF (NCT01877915) 
[129]. It will assess the effectiveness and safety of rivaroxaban compared with placebo (both in 
addition to standard therapy for HF and CAD) in reducing the risk of death, MI, and stroke in patients 
with HF and significant CAD (see Supporting Information, Table 1, in the online version of this article). 
 
Related fields of research 
"Cryptogenic" stroke: Embolic Stroke of Undetermined Source (ESUS) 
Ischemic stroke accounts for 80% of all strokes [130]. Of these, 25% are ‘embolic stroke of 
undetermined source’ (ESUS), previously designated as cryptogenic stroke [131], which is defined as 
a nonlacunar brain infarct (subcortical infarct >1.5 cm on computed tomography or >2.0 cm on 
magnetic resonance imaging) without proximal arterial stenosis or an identified source of 
cardioembolism (including AF). Recurrent stroke in patients with ESUS is reported inconsistently, 
because of differing diagnostic and prognostic criteria and lack of standardization, but ranges from 
3% to 6% per year [131]. Treatment options to prevent recurrent stroke after ESUS are limited, and 
the mechanisms of stroke generation may be heterogeneous. A high proportion of older patients 
(≥55 years) who have an ESUS may have underlying paroxysmal AF [132]. Several studies observed 
paroxysmal AF in around 10–20% of patients with cryptogenic ischemic stroke [131]. The duration of 
paroxysmal AF can be short, lasting only minutes or seconds; therefore, anticoagulation therapy may 
not be justified [131]. Evaluating patients for AF after an ESUS is important because of the treatment 
implications (Supplemental Table 3). 
 
The CRYSTAL AF study evaluated AF incidence and time to AF detection in patients with ESUS using 
an insertable cardiac monitor [133]. Continuous monitoring detected AF in 30% of these patients 
versus 3% with standard medical care at 36-month follow-up [134]. Of patients with detected AF, 
97% were prescribed anticoagulation therapy [134]. Another study, EMBRACE, confirmed that 
paroxysmal AF was common among patients aged ≥55 years with recent ESUS or transient ischemic 
attack [132]. In summary, prolonged electrocardiogram monitoring substantially improved AF 
detection and increased the rate of anticoagulant treatment [132]. 
 
The efficacy and safety of dabigatran (RE-SPECT ESUS; NCT02239120) and apixaban (ATTICUS; 
NCT02427126) in patients with prior ESUS is currently being investigated. The hypothesis that a 
NOAC could be superior to aspirin in reducing the risk of recurrent stroke and SE was not confirmed 
in the NAVIGATE ESUS study. This finding has opened the field for new studies to determine the 
underlying mechanism of these strokes, including the complications of atherothrombotic disease in 
sinus rhythm [113,114,135]. 
 
Future potential applications for NOACs? 
Beyond the unmet needs in defined patient subgroups with vascular disease, other patient groups 
could benefit from NOAC treatment. 
 
Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease associated 
with hemodynamic abnormalities. It occurs in ~0.2% of the general population [136]. Stroke 
incidence in patients with HCM and AF is ~21–23% [136] and, therefore, anticoagulation therapy is 
recommended independent of CHA2DS2-VASc score [31]. Specific data for NOACs in patients with 
HCM are not available, but these agents may be considered [136]. 
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Anticoagulation based on monitoring atrial tachyarrhythmia 
Implanted cardiac devices can detect atrial tachyarrhythmias, allowing assessment of the correlation 
between AF or atrial flutter and stroke risk, and the feasibility of ‘pill-in-the-pocket’ anticoagulation 
based on daily remote transmissions from an implanted cardiac device. The IMPACT (In-hospital 
Mortality for PulmonAry embolism using Claims daTa) study assessed whether the initiation and 
withdrawal of oral anticoagulant therapy (VKAs, rivaroxaban, dabigatran, or apixaban) guided by 
continuous ambulatory monitoring of an atrial electrogram improves clinical outcomes versus 
conventional clinical management in patients with implanted dual-chamber cardiac 
resynchronization therapy defibrillator devices [137]. This study was terminated early (2 years’ 
median follow-up) based on no difference in primary endpoints (stroke, SE, and major bleeding) 
between groups, suggesting that early initiation and withdrawal of anticoagulation based on 
remotely detected atrial tachyarrhythmias did not prevent thromboembolism and bleeding [137]. 
The REACT.COM pilot study (NCT01706146) concluded that intermittent anticoagulation with 
dabigatran, rivaroxaban, or apixaban guided by a continuous AF-sensing implantable cardiac monitor 
(Reveal XT) with remote data transmission capabilities is feasible [138]. This allows remote and 
continuous evaluation of patients for arrhythmias including AF recurrences, even for brief 
asymptomatic episodes. Whether brief episodes of AF (e.g., <6 minutes) are prognostically important 
is uncertain, and a role for NOACs in such patients is undetermined.  
 
REVEAL AF (NCT01727297) uses the Reveal implantable cardiac monitor and aims to determine the 
incidence of AF in patients suspected to be at high risk of AF, and to understand how physicians 
manage these patients after AF has been detected [139]. This study aimed to identify which patient 
characteristics are most predictive of developing AF. A total of 385 patients with a CHADS2 score of 
≥3, or a CHADS2 score of 2 plus at least one additional AF risk factor (to include CAD, renal 
impairment, sleep apnea or chronic obstructive pulmonary disease), were followed up for a mean of 
22.5 months and showed an AF detection rate of 6.2% at 30 days [140]. The detection rate increased 
throughout the monitoring period. A high incidence of AF (lasting ≥6 minutes) was detected by 
cardiac monitoring in ~30% of high-risk patients at 18 months, increasing to 40% at 30 months [140]. 
Undetected subclinical AF may present in a substantial proportion of patients with risk factors for AF 
and stroke. Prophylactic therapies may be beneficial in these patients, and further research is 
required [140]. 
 
Other ongoing studies (e.g., ARTESiA [NCT01938248] and NOAH-AFNET 6 [NCT02618577]) are 
assessing oral anticoagulation versus standard therapy for ischemic stroke and SE risk reduction in 
patients with device-detected subclinical AF and additional stroke risk factors. 
 
Device interventions for stroke prevention in patients with AF (LA/LAA thrombi) 
Permanent treatment options, such as surgery to remove or close the LAA or percutaneous closure 
devices, have been explored to circumvent the risk of bleeding associated with long-term 
anticoagulation therapy. Although surgical closures are often incomplete, the WATCHMAN, 
AMPLATZER, and LARIAT devices are the 3 closure devices that are currently being studied for 
percutaneous LAA closure [141]. The WATCHMAN device is the most studied and is noninferior to 
warfarin for preventing the combined outcomes of stroke, SE, and cardiovascular death, and superior 
for preventing cardiovascular and all-cause mortality [142]. A meta-analysis of PROTECT-AF and 
PREVAIL randomized trials, and 2 nonrandomized studies, consisting of 2406 patients with 5931 
patient-years of follow-up, found significantly fewer hemorrhagic strokes, 
cardiovascular/unexplained deaths and nonprocedural bleeding events in patients receiving LAA 
closure with the WATCHMAN device compared with patients treated with warfarin, with similar rates 
of all-cause stroke or SE between the 2 groups [143].  
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Valve disease and valve replacement 
Antithrombotic therapy is recommended after valve replacement with mechanical prostheses, 
bioprostheses or transcatheter aortic valve replacement (TAVR) and should be adapted according to 
the type and site of prosthesis, the period considered and patient characteristics [144]. Combination 
therapies of both anticoagulation and antiplatelet agents have not been robustly studied in these 
patients. The RE-ALIGN phase II study assessed dabigatran versus warfarin in patients who had 
undergone aortic or mitral valve replacement with mechanical valves. The trial was terminated 
prematurely owing to increased rates of thromboembolic and bleeding complications in the 
dabigatran group, despite the use of higher doses of dabigatran than used in patients with AF [146]. 
Although not known, it has been assumed that as dabigatran was not suitable in the prevention of 
thromboembolic events in patients with mechanical heart valves, this finding can be applied to all 
NOACs. GALILEO (NCT02556203) is an ongoing phase III study in patients after TAVR, assessing 
rivaroxaban plus ASA followed by rivaroxaban alone versus ASA plus clopidogrel followed by ASA 
alone for superiority in reducing death or first thromboembolic events and noninferiority in the 
occurrence of primary bleeding events. Results are expected in 2018. Ongoing studies assessing the 
benefit–risk of NOACs in patients with bioprosthetic or rheumatic valves include the RIVER 
(NCT02303795) and INVICTUS studies (NCT02832544/NCT02832531). 
 
Mitral stenosis 
Patients with hemodynamically significant mitral stenosis were excluded from the trials of stroke 
prevention with the NOACs, despite being at increased thrombotic, embolic, and stroke risks. 
Optimal anticoagulation control with VKAs is challenging, especially in regions where rheumatic heart 
disease is most prevalent. NOACs may have an important role in such patients [147]. Launched in 
June 2016, INVICTUS is a worldwide program consisting of a registry of 20,000 patients and 2 clinical 
trials that will examine if rivaroxaban can safely reduce strokes in patients with rheumatic heart 
disease [148]. 
 
Bioprosthetic mitral valves 
Guidelines currently recommend VKAs as the first-line oral anticoagulation therapy in patients with 
AF and bioprosthetic mitral valves owing to lack of evidence with NOACs in this setting [149]. The 
phase II RIVER trial (NCT02303795) will assess rivaroxaban versus VKAs for the prevention of 
disabling strokes, major bleeding events, all-cause death, valve thrombosis, and noncentral nervous 
system SE in patients with AF and bioprosthetic mitral valves. Results are expected in late 2018/early 
2019. 
 
Phospholipid syndrome 
The current mainstay for the prevention of VTE in patients with thrombotic APS is long-term 
anticoagulation with VKAs such as warfarin [150]. Several ongoing phase II/III studies are assessing 
rivaroxaban versus warfarin in patients with thrombotic APS with or without systemic lupus 
erythematosus, such as RAPS (NCT02116036) [150], and in high-risk patients with triple APS 
(NCT02157272) [151]. 
 
End-stage renal dysfunction and hemodialysis 
Patients with severe renal dysfunction and those requiring hemodialysis were excluded from stroke 
prevention trials with the NOACs [16-19]. However, such patients are at increased risk of thrombotic 
and bleeding events. Trials with apixaban and edoxaban suggest that the factor Xa inhibitors may 
have a favorable benefit–risk balance compared with warfarin in such patients [152,153]. A small 
phase I study with apixaban has led to its FDA approval in patients with AF and end-stage renal 
disease (ESRD) [154,155]. A further small-scale phase I study with rivaroxaban in individuals with 
ESRD (but otherwise healthy) showed that deterioration of renal filtration function from severe to 
ESRD did not have a significant impact on rivaroxaban pharmacokinetics and pharmacodynamics 
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beyond changes observed with moderate or severe renal impairment [156]. Trials with patients 
indicated for anticoagulation have yet to be conducted. 
 
Cognitive decline 
Debate exists over the association between AF and cognitive decline, even beyond the association 
with recurrent embolic stroke. A recent review concludes that AF is independently associated with 
cognitive decline, even among patients with no clinical history of stroke [157]. Cognitive decline is 
associated with stroke and silent cerebral infarcts, and patients with AF have higher rates of silent 
cerebral infarcts than patients without AF. Among patients with AF, low scores on the Mini Mental 
State Examination have been associated with out-of-range international normalized ratio values and 
an increased risk of vascular events and bleeding. However, the impact of anticoagulation on silent 
cerebral infarcts remains unknown; therefore, clinical trials evaluating the effect of NOACs on 
cognitive decline in patients with AF would be of value [157]. 
 
Conclusions 
 
There are significant unmet medical needs for several arterial thromboembolic-related conditions. 
The NOACs may provide new treatment options in these areas and studies to address these unmet 
clinical needs are currently ongoing. Observational studies with NOACs enable assessment of patient 
management, safety, and observed outcomes in an extended range of patients, including many 
excluded from clinical trials. Beyond the currently approved NOAC indications, there are 
cardiovascular and cerebrovascular conditions where further clinical studies are needed to assess the 
benefit–risk profile of the NOACs and the potential for practical management advantages. In this 
review, the emphasis has been placed on rivaroxaban as the NOAC with the broadest range of 
indications. This agent is also being investigated in further indications across several patient groups, 
for example, indications in the post-ACS setting. NOACs should be assessed at an individual level 
when considering future indications and use in patient subgroups that have not been investigated 
previously. 
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Figure legends 
 
Figure 1. Rates of major bleeding with rivaroxaban in ROCKET AF, the Dresden NOAC Registry, the US 
Department of Defense postmarketing surveillance study, and XANTUS. Results are not intended for 
direct comparison. Abbreviations: NOAC, nonvitamin K antagonist oral anticoagulant; ROCKET AF, 
Rivaroxaban Once daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for 
Prevention of Stroke and Embolism Trial in Atrial Fibrillation; XANTUS, Xarelto for Prevention of 
Stroke in Patients with Atrial Fibrillation. 
 
Figure 2. Distribution of CHA2DS2-VASc and pattern of anticoagulant treatment. Increase in use of 
NOACs from Cohort 1 to Cohort 5; overuse in patients with CHA2DS2-VASc = 0. 53,053 prospective 
patients were enrolled in 5 sequential cohorts from 2010 to 2016. Cohort 1 (2010–2011), n = 5,499; 
Cohort 2 (2011–2013), n = 11,662; Cohort 3 (2013–2014), n = 11,462; Cohort 4 (2014–2015), n = 
11,296; Cohort 5 (2015–2016), n = 12,134.  
AP: antiplatelet; DTI: direct thrombin inhibitor; FXa factor Xa inhibitor; VKA: vitamin K antagonist. 
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